SCHEMBL7736895

SCHEMBL7736895

CC1(C(=O)O)OCCC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.32
CYP2C9 P11712 1/20 0.32
FFAR3 O14843 1/20 0.32
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 2/20 0.30
NPC1 O15118 2/20 0.30
TP53 P04637 1/20 0.30
NFKB1 P19838 1/20 0.30
CYP2C19 P33261 1/20 0.30
THPO P40225 1/20 0.30
STAT6 P42226 1/20 0.30
HIF1A Q16665 1/20 0.30
GMNN O75496 1/20 0.30
MTOR P42345 1/20 0.30
RAB9A P51151 1/20 0.30
BLM P54132 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7387109 0.83 ITGB1 (0.34)
SCHEMBL23388837 0.69 NPC1 (0.37) NPC1
SCHEMBL6124305 0.69
SCHEMBL16932247 0.67 SMN1; SMN2 (0.33) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL3009778 0.67 LMNA (0.34) LMNACYP2C9FFAR3PTGS1PTGS2
SCHEMBL3116526 0.64 FFAR3 (0.39) LMNAFFAR3MAPK1NPC1TP53
SCHEMBL15106146 0.63 PTGS1 (0.39) FFAR3PTGS1PTGS2CYP1A2CYP3A4
SCHEMBL13788900 0.62
SCHEMBL12083425 0.62 LMNA (0.38) LMNACYP2C9TSHRTP53
SCHEMBL11442064 0.61 CYP1A2 (0.49) LMNACYP2C9FFAR3PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010120232-A1 A PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY YKI, YTKEMISKA INSTITUTET AB (SE) 2010-10-21 WO disclosed
US-6420418-B1 INHIBITION AND PREVENTION OF LEUKOCYTE ADHESION; USED TO TREAT ADHESION-MEDIATED DISEASES SUCH AS ASTHMA, ALLERGIC RHINITIS, MULTIPLE SCLEROSIS; ATHEROSCLEROSIS, AND INFLAMMATORY BOWEL DISEASE MERCK & CO., INC. 2002-07-16 US disclosed